Haemonetics Corporation (HAE) Stock Analysis
Recovery setup
Healthcare · Medical Devices
Sell if holding. At $59.56, A.R:R 1.2:1 is below the 1.5:1 minimum. Reward from here is too thin for a buy — the engine flags exit. Additional concerns: Leverage penalty (D/E 1.5): -1.0; Concentration risk — Supplier: single third-party vendor.
Haemonetics is a global medical technology company with Plasma (39.3%), Hospital (41.5%), and Blood Center (19.2%) segments, selling automated collection systems, disposables, and software to plasma centers, hospitals, and blood collectors. Top 10 customers represent ~42% of net... Read more
Sell if holding. At $59.56, A.R:R 1.2:1 is below the 1.5:1 minimum. Reward from here is too thin for a buy — the engine flags exit. Additional concerns: Leverage penalty (D/E 1.5): -1.0; Concentration risk — Supplier: single third-party vendor. Chart setup: Death cross but MACD improving, RSI 49. Score 5.7/10, moderate confidence.
Passes 7/9 gates (positive momentum, clean insider activity, no SEC red flags, news events none recent, earnings proximity 78d clear, semi cycle peak clear, materials cycle peak clear). Fails on favorable risk/reward ratio. Suitability: aggressive.
Recent Developments — Haemonetics Corporation
Latest news
- Chiesi strikes $1.9B deal for KalVista and its oral HAE therapy - FirstWord Pharma — FirstWord Pharma positive
- Haemonetics Earnings: What To Look For From HAE - StockStory — StockStory neutral
- Haemonetics Earnings: What To Look For From HAE - FinancialContent — FinancialContent neutral
- NTLA Falls 4% Despite Strong Phase III HAE Data, Initiates Rolling BLA - The Globe and Mail — The Globe and Mail neutral
- Will VASCADE MVP XL’s Expanded FDA Labeling Shift Haemonetics’ (HAE) Electrophysiology Growth Narrative - Yahoo Finance — Yahoo Finance positive
Generated 2026-05-20T21:13:14Z.
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- MEDIUMCustomertop-10 customers42%10-K Item 1: 'In fiscal 2025, our ten largest customers accounted for approximately 42% of our net revenues.'
- HIGHSuppliersingle third-party vendor10-K Item 1A: 'we rely on a single vendor to support several of our business processes, including customer service and support and elements of enterprise technology, procurement, accounting and human resources.'
Material Events(8-K, last 90d)
- 2026-05-01Item 5.02LOWDirector Charles J. Dockendorff will not stand for re-election at the 2026 Annual Meeting of Shareholders. Not the result of any disagreement. Will continue serving until the meeting.SEC filing →
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. Full disclaimer
Rating Breakdown
3 floor-breakers
Technicals below the gate floor. Component breakdown shows what dragged the score down.static
Ranks in the bottom of its industry peers on the composite signal. Better names in the same sector exist.static
Growth below the gate floor. Component breakdown shows what dragged the score down.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. At $59.56, A.R:R 1.2:1 is below the 1.5:1 minimum. Reward from here is too thin for a buy — the engine flags exit. Additional concerns: Leverage penalty (D/E 1.5): -1.0; Concentration risk — Supplier: single third-party vendor. Chart setup: Death cross but MACD improving, RSI 49. Prior stop was $55.39. Score 5.7/10, moderate confidence.
Take-profit target: $69.77 (+17.1% upside). Prior stop was $55.39. Stop-loss: $55.39.
Concentration risk — Supplier: single third-party vendor; Leverage penalty (D/E 1.5): -1.0; Weak growth.
Haemonetics Corporation trades at a P/E of 27.7 (forward 9.9). TrendMatrix value score: 7.5/10. Verdict: Sell.
15 analysts cover HAE with a consensus score of 3.9/5. Average price target: $80.
What does Haemonetics Corporation do?Haemonetics is a global medical technology company with Plasma (39.3%), Hospital (41.5%), and Blood Center (19.2%)...
Haemonetics is a global medical technology company with Plasma (39.3%), Hospital (41.5%), and Blood Center (19.2%) segments, selling automated collection systems, disposables, and software to plasma centers, hospitals, and blood collectors. Top 10 customers represent ~42% of net revenues; the Plasma segment is concentrated among a limited number of large biopharmaceutical customers. Business processes are outsourced to a single third-party vendor.